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Accepted 30 December 2013To further strengthen the hypothesis of transfusion-In the December issue, Kekre et al. [1] provided very
interesting data about the incidence of cytomegalovirus
(CMV) infections in patients with allogeneic stem cell
transplantation. In contrast to 2 other reports [2,3], active
CMV infections and even CMV disease were detected in this
study. Comparing the classic transfusion strategy of leu-
koreduced and CMV-seronegative blood units with the cur-
rent approach of only leukoreduced but CMV-untested units,
there was no signiﬁcant difference in the incidence of CMV
viremia or CMV disease. The authors assume that all 4 CMV
infections in the study period were transfusion related and
presumably caused by seronegative donors in the window
phase of their primary CMV infection. To support this hy-
pothesis, a publication of our group [4] is cited to report
window periods being as long as months.
Because only 1 seronegative sample of each donor was
analyzed in the cited study, no conclusions about the dura-
tion of the window period can be drawn from these data. In
other studies we were able to show that window period
donations are rare and contain less CMV DNA than donations
from primarily seropositive donors [5,6]. Donors in the early
seropositive phase of their primary CMV infection were also
responsible for higher peak CMV DNA concentrations in
CMV-untested donations compared with CMV-seronegative
donations in a study of almost 23,000 donations [7]. Never-
theless, seronegative blood products containing CMV might
be more infectious than units from seropositive donors with
potentially neutralizing antibodies.* Correspondence and reprint requests: Malte Ziemann, MD, Institute of
Transfusion Medicine, University Hospital of Schleswig-Holstein, Ratze-
burger Allee 160, 23538 Lübeck, Germany.
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http://dx.doi.org/10.1016/j.bbmt.2013.12.572transmitted CMV infections, it would be interesting to
determine how many donors, who donated blood products
for the patients with CMV infection, later developed CMV
antibodies. Ideally, the number of seroconverted donors is
greater for patients with CMV infection than for other pa-
tients. If stored serum samples were still available from these
donors, they could also be tested for CMV DNA.REFERENCES
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